SNS-314 (CAS 1057249-41-8)
QUICK LINKS
SNS-314 is a compound that is studied primarily for its role as an aurora kinase inhibitor. In cell biology research, SNS-314 is utilized to investigate the regulation of mitosis, since aurora kinases are critical for chromosome alignment, segregation, and cytokinesis. The compound′s ability to inhibit these kinases allows researchers to examine the consequences of disrupting these processes and to understand the cell cycle better. Studies involving SNS-314 also delve into the mechanisms of mitotic spindle formation and the dynamics of microtubule organization. Additionally, in the field of cancer research, SNS-314 is of interest for its potential to elucidate the pathways that contribute to uncontrolled cell proliferation.
SNS-314 (CAS 1057249-41-8) References
- The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. | VanderPorten, EC., et al. 2009. Mol Cancer Ther. 8: 930-9. PMID: 19372566
- SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. | Arbitrario, JP., et al. 2010. Cancer Chemother Pharmacol. 65: 707-17. PMID: 19649632
- 3D-QSAR and molecular docking studies on derivatives of MK-0457, GSK1070916 and SNS-314 as inhibitors against Aurora B kinase. | Zhang, B., et al. 2010. Int J Mol Sci. 11: 4326-47. PMID: 21151441
- Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. | Baldini, E., et al. 2012. Clin Ter. 163: e307-13. PMID: 23099978
- A New Quantitative Cell-Based Assay Reveals Unexpected Microtubule Stabilizing Activity of Certain Kinase Inhibitors, Clinically Approved or in the Process of Approval. | Ramirez-Rios, S., et al. 2020. Front Pharmacol. 11: 543. PMID: 32425788
- Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. | Krushkal, J., et al. 2020. Clin Epigenetics. 12: 93. PMID: 32586373
- High-throughput kinase inhibitor screening reveals roles for Aurora and Nuak kinases in neurite initiation and dendritic branching. | Blazejewski, SM., et al. 2021. Sci Rep. 11: 8156. PMID: 33854138
- High-Throughput Assay to Screen Small Molecules for Their Ability to Prevent Sickling of Red Blood Cells. | Nakagawa, A., et al. 2022. ACS Omega. 7: 14009-14016. PMID: 35559170
- Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells. | Yi, YW., et al. 2022. Cancers (Basel). 14: PMID: 36358633
- An extensive bioinformatics study on the role of mitochondrial solute carrier family 25 in PC and its mechanism behind affecting immune infiltration and tumor energy metabolism. | Zhang, Q., et al. 2022. J Transl Med. 20: 592. PMID: 36514121
- The Aurora Kinase Inhibitor CYC116 Promotes the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells. | Ji, S., et al. 2022. Mol Cells. 45: 923-934. PMID: 36572561
- Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. | Skowron, MA., et al. 2023. Mol Med. 29: 40. PMID: 36991316
- Aurora B Inhibitors as Cancer Therapeutics. | Kovacs, AH., et al. 2023. Molecules. 28: PMID: 37110619
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SNS-314, 5 mg | sc-474005 | 5 mg | $270.00 |